A former researcher at Amgen (NYSE: AMGN) has been named as the new chief scientific officer of UK-based cellular immunotherapy company Cell Medica.
Luis Borges began his career at Immunex, an immunology-based biotech company which was acquired by Amgen, and he was involved in several successful hematology and oncology drug development programs with the US biotech major.
"His proven R&D management expertise will accelerate and de-risk our product generation capabilities"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze